Investment Thesis
After reporting their second-quarter earnings, Fulgent Genetics (NASDAQ:FLGT) dropped nearly 15% after missing estimates on both the top and bottom line. This was primarily due to decreased COVID testing, which has become a large
Fulgent Genetics Misses Estimates, But I Am Still Bullish
Summary
- Fulgent Genetics reported earnings recently, on August 9th, 2021.
- Fulgent dropped nearly 15% after the earnings report, likely due to misses on both revenue and EPS estimates.
- Despite missing estimates, Fulgent had an strong quarter, showing strong growth along with other announcements that will strengthen the long-term opportunity of Fulgent.
He is a college student who has found a deep thirst for learning and investing. Being very young, he has leaned toward very long-term investments and growth stocks, primarily in tech. He does, however, love consumer goods companies as well. Currently, he is studying International Business and Economics.
Analyst’s Disclosure:I/we have a beneficial long position in the shares of FLGT either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.